😎 Summer Sale Exclusive - Up to 50% off AI-powered stock picks by InvestingProCLAIM SALE

Jazz Pharmaceuticals' chief accounting officer sells shares worth over $17k

Published 2024-06-11, 08:20 p/m

Jazz Pharmaceuticals plc's (NASDAQ:JAZZ) Senior Vice President and Chief Accounting Officer, Patricia Carr, has recently sold a total of 163 ordinary shares at an average price of $108.825, amounting to a transaction value of over $17,000. The transaction occurred on June 7, 2024, and was disclosed in a recent filing.

The sale has slightly reduced Carr's holdings in the company, but she still retains 6,596 ordinary shares following the transaction. It's worth noting that the shares sold were acquired under a Section 423 Employee Stock Purchase Plan on May 31, 2024, as indicated by a footnote in the filing.

Investors often monitor insider transactions as they can provide insights into an executive's view of the company's future prospects. However, it's important to consider that insider sales can occur for various reasons and may not necessarily reflect a negative outlook.

Jazz Pharmaceuticals, headquartered in Dublin, Ireland, is a biopharmaceutical company known for its development and commercialization of therapies for diverse medical needs. The company's stock is traded on the NASDAQ under the ticker symbol JAZZ.

The details of the transaction were made public through a Form 4 filing with the Securities and Exchange Commission, which is a standard requirement for officers, directors, and significant shareholders to report their trading activities in company stock.

In other recent news, Jazz Pharmaceuticals has been in the spotlight with several significant developments. The firm's suvecaltamide, a treatment for essential tremor (ET), is under evaluation in a phase IIb trial, with RBC (TSX:RY) Capital Markets maintaining an Outperform rating and a $176.00 price target for the company. Goldman Sachs (NYSE:GS) also initiated coverage on Jazz Pharmaceuticals with a Buy rating, setting a price target of $169.00, while TD (TSX:TD) Cowen sustained a Buy rating despite a price target revision following the company's first-quarter revenue report.

Jazz Pharmaceuticals has also been making strides in its pipeline, with Phase 2b suvecaltamide data expected in 2024 and a PDUFA date set in November for potential approval of zanidatamab in second-line HER2+ biliary tract cancer. Additionally, the company presented thirteen abstracts at the SLEEP 2024 conference, focusing on advancements in the treatment of serious sleep disorders.

Despite challenges in patient reimbursement affecting first-quarter revenue, Jazz Pharmaceuticals maintains its full-year 2024 revenue guidance, projected to be between $4 billion and $4.2 billion. These are recent developments that investors should consider while assessing the company's performance and future potential.

InvestingPro Insights

Investors eyeing Jazz Pharmaceuticals plc (NASDAQ:JAZZ) might be intrigued by the company's recent financial and market performance. With a solid market capitalization of $6.96 billion, Jazz Pharmaceuticals stands as a substantial player in the biopharmaceutical space. A key metric that stands out is the company's impressive gross profit margin, which, as of the last twelve months ending Q1 2024, was at a striking 92.65%. This figure not only reflects the company's ability to maintain a high level of profitability but also underscores its efficiency in managing production and operational costs.

Moreover, the company's stock has been characterized by low price volatility, an attribute that might appeal to investors looking for stability in their portfolio. This trait is complemented by the fact that Jazz Pharmaceuticals' liquid assets surpass its short-term obligations, indicating a strong liquidity position that can reassure investors of the company's ability to meet its immediate financial commitments.

For those interested in the company's forward-looking potential, two "InvestingPro Tips" might hold particular interest. Firstly, management's aggressive share buyback strategy could signal confidence in the company's valuation and future prospects. Secondly, with 8 analysts having revised their earnings upwards for the upcoming period, there is a positive sentiment surrounding the company's expected financial performance.

To delve deeper into Jazz Pharmaceuticals' potential and unlock more strategic insights, investors can explore additional "InvestingPro Tips" available at https://www.investing.com/pro/JAZZ. In fact, there are 11 more tips listed in InvestingPro, providing a comprehensive analysis of the company's outlook. For those considering a subscription, remember to use the coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription, which could be a valuable investment in making informed financial decisions.

Jazz Pharmaceuticals' next earnings date is slated for August 6, 2024, which will be a significant event for investors and analysts tracking the company's performance. With the current fair value estimated by analysts at $187 and InvestingPro's fair value at $149.66, there seems to be a range of opinions on the company's intrinsic value, which could merit further investigation by prospective investors.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.